Search Technologies
Displaying 121 - 130 of 226 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Use of ELA peptide for treatment of cardiovascular disease and for improving fluid homeostasis
Published Tuesday, October 20, 2015Cardiovascular disease (CVD) continues to be one of America’s most serious and costly health issues. Though many therapeutic options exist to treat CVD, the majority of treatments address the symptoms of the disease and not the disease itself. This technology is a new class of therapeutic fusion proteins using the hormone Elabela (ELA) to...
Investigator(s): Da-Wei Gong (Lead PI)
Categories: Therapeutics, Biologics, Methods of Treatment
Keyword(s): MI, peptide, heart failure, myocardial infarction, cardiovascular, obesity, ELA, apelin
Docket: DG-2014-128
-
Monoclonal antibodies to polycystin-1 protein
Published Monday, October 19, 2015Polycystin-1 (PC1) is a protein encoded by the Polycystic Kidney Disease 1 (PKD1) gene. It induces resistance to apoptosis and spontaneous proliferation of kidney tubular epithelial cells. Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that results in formation of fluid filled cysts in the kidney. As the...
Investigator(s): Feng Qian, Terry Watnick
Categories: Research Tools, Antibodies, & Reagents
Keyword(s): PKD, polycystic kidney disease polycystin-1
Docket: FQ-2015-089
-
Antibacterial monomers, antibacterial resins and dental composites comprising the antibacterial resins
Published Thursday, October 15, 2015A major clinical problem associated with dental restorations is secondary cary formation and tooth restoration fractures. To address this issue, a new dental resin developed at the University of Maryland, Baltimore, was created that possesses superior mechanical strength and antimicrobial properties. The formulation...
Investigator(s): Huakun Xu, Michael Weir
Categories: Dental
Keyword(s): dental, cary, restorative, composite
Docket: HX-2013-023
-
Motion Artifact Suppression in 4D CT Reconstruction with Iterative Back Projection
Published Thursday, October 15, 2015Computational tomography (CT) is computer-aided reconstruction imaging of X-ray projection data and is commonly used for diagnostic purposes. Although image quality is essential for diagnostic accuracy, CT images are prone to artifacts because the image is reconstructed using multiple measurements and a single error in...
Investigator(s): Byong Yong Yi, Nilesh Mistry, Cedric X Yu, Giovanni Lasio
Categories: Imaging devices, Software + Algorithm
Docket: BY-2014-089
-
Method for Image Reconstruction of Moving Radionuclide Source Distributions
Published Monday, September 28, 2015Positron emission tomography (PET) is a functional imaging technique for studying biological processes in vivo for pre-clinical and clinical studies. PET compounds labelled with short-lived positron emitters are delivered to a subject (human, animals or plants). The raw PET scanning data is reconstructed...
Investigator(s): Mark Smith
Categories: Imaging, Software + Algorithm, Other
Keyword(s): PET, SPECT, Image reconstruction, nuclear medicine
Docket: MS-2009-091
-
Anti-shark IgNar mouse monoclonal (GA8) antibody
Published Tuesday, September 22, 2015The cartilaginous fish (sharks, skates, and rays) have a human-type adaptive immune system as well as immunoglobulins (Igs). In addition to the heavy-light chain heterodimeric isotypes (IgM and IgW), sharks also produce a novel isotype called IgNAR. IgNAR is a heavy chain homodimer that does not associate with light chains....
Investigator(s): Martin Flajnik
Categories: Research Tools, Antibodies, & Reagents
Docket: MF-2009-077
-
A stable Receptor-Associated Protein (RAP) protein
Published Tuesday, September 22, 2015A novel Stable Receptor-Associated Protein (RAP), an antagonist of lipoprotein receptor-related protein 1 (LRP1). Dr. Strickland at UMB has developed a stable RAP D3 domain (with 6 mutations) that is resistant to both pH- and heat-induced denaturation. The molecule binds to lipoprotein receptor-related protein 1 (LRP1) with high affinity...
Investigator(s): Dudley Strickland
Categories: Research Tools, Antibodies, & Reagents
Keyword(s): RAP Protein stable
Docket: DS-2015-111
-
Use of Micro-RNA Mimics as Therapeutic Agents for Inhibition of Neuronal Apoptosis Following Traumatic Brain Injury.
Published Tuesday, August 25, 2015Reduced blood flow to the brain due to thrombosis, embolism, cardiac arrest, or injury, can result in focal or global cerebral ischemia. Ischemia leads to alterations in brain metabolism, reduction in metabolic rates, and subsequent neuronal death. Ischemia can have irreversible sequela. Post-injury treatment to curtail cell death due to acute...
Investigator(s): Alan Faden, Bogdan Stoica, Boris Sabirzhanov
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Traumatic Brain Injury, micro RNA, miRNA mimics, ischemia
Docket: AF-2014-011
-
Compositions and Methods for Determining the Likelihood of Appendicitis
Published Tuesday, August 25, 2015Appendicitis is a condition that is easily treated through the surgical removal of the appendix. However, delays in diagnosis beyond 24-36 hours from the start of symptoms can lead to an increased risk of mortality, morbidity, and costs due to complications. Diagnosis is complicated by the heterogeneous clinical presentation of...
Investigator(s): Anthony Sandler, Claire M. Fraser, Emmanuel Mongodin, Hope Jackson, Katherine Davenport, Steven L. Zeichner
Categories: Diagnostics, Biomarker, Genomics/Proteomics/Database
Keyword(s): Appendicitis, Appendix, Microbiota, bacteria
Docket: CF-2014-074
-
Novel LRKK2 GTP-Binding Domain Inhibitors for Treatment of Parkinson's Disease and Neuroinflammatory Disorders
Published Tuesday, July 7, 2015Parkinson’s disease (PD) is an age-related disorder affecting an estimated 1-1.5 million Americans. Current therapies are only able to alleviate PD symptoms and aberrant side effects from prolonged use (5-10yrs) of these drugs can parallel the severity of the disease itself. Researchers at the University of Maryland,...
Investigator(s): Wanli Smith, Fengtian Xue, Alexander Mackerell Jr.
Keyword(s): small molecule inhibitor
Docket: WS-2014-161